Li Watsek

Stock Analyst at Cantor Fitzgerald

(0)
# 4941
Out of 5,297 analysts
92
Total ratings
31.76%
Success rate
-31.29%
Average return
Main Sectors:
Top Industries:
22 Stocks
Name Action Price Target Current % Upside Ratings Updated
ZLAB Zai Lab
Reiterates: Overweight
n/a
n/a n/a 1 Mar 27, 2025
ACRV Acrivon Therapeutics
Reiterates: Overweight
n/a
n/a n/a 2 Mar 26, 2025
TARA Protara Therapeutics
Initiates Coverage On: Overweight
n/a
n/a n/a 1 Mar 14, 2025
ASND Ascendis Pharma
Maintains: Overweight
170 200
152.32 31.3% 17 Feb 25, 2025
ARVN Arvinas
Reiterates: Overweight
n/a
n/a n/a 5 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 7 Jan 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 10 Dec 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 7 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 4 Oct 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
20 20
4.79 317.54% 2 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 1 May 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
3
1.09 175.23% 4 Nov 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
220
7.43 2860.97% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
26
n/a n/a 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
0.77 549.35% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
1140
1.71 66566.67% 2 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 38
1.93 1868.91% 1 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75 69
n/a n/a 2 Aug 9, 2022